Holen Sie sich die Stockscreener-App
136.10
1.03%
1.39
Vorhandelsmarkt:
136.61
0.51
+0.37%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt A?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$134.71
Offen:
$134.69
24-Stunden-Volumen:
1.75M
Relative Volume:
0.76
Marktkapitalisierung:
$38.44B
Einnahmen:
$7.23B
Nettoeinkommen (Verlust:
$1.41B
KGV:
27.33
EPS:
4.979
Netto-Cashflow:
$1.09B
1W Leistung:
+1.88%
1M Leistung:
+6.05%
6M Leistung:
-2.54%
1J Leistung:
+19.99%
1-Tages-Spanne:
$133.72
$136.26
1-Wochen-Bereich:
$132.49
$136.91
52-Wochen-Spanne:
$108.35
$160.27
Agilent Technologies Inc Stock (A) Company Profile
Firmenname
Agilent Technologies Inc
Sektor
Branche
Telefon
(408) 345-8886
Adresse
5301 STEVENS CREEK BLVD, SANTA CLARA, CA
Compare A vs TMO, DHR, IDXX, NTRA
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
A
Agilent Technologies Inc
|
136.10 | 38.44B | 7.23B | 1.41B | 1.09B | 4.979 |
TMO
Thermo Fisher Scientific Inc
|
543.19 | 201.86B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
205.01 | 145.10B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
576.07 | 45.44B | 4.45B | 1.10B | 1.06B | 13.59 |
NTRA
Natera Inc
|
269.83 | 38.64B | 2.50B | -226.32M | 71.51M | -1.6412 |
Agilent Technologies Inc Stock (A) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-20 | Eingeleitet | HSBC Securities | Buy |
| 2026-01-05 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2025-12-15 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2025-12-09 | Eingeleitet | Goldman | Buy |
| 2025-12-02 | Eingeleitet | Morgan Stanley | Overweight |
| 2025-10-08 | Eingeleitet | Rothschild & Co Redburn | Buy |
| 2025-10-08 | Hochstufung | UBS | Neutral → Buy |
| 2025-02-10 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2024-08-28 | Eingeleitet | Wells Fargo | Overweight |
| 2024-07-10 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-06-27 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2024-06-03 | Fortgesetzt | Jefferies | Hold |
| 2024-04-05 | Hochstufung | Stifel | Hold → Buy |
| 2023-12-13 | Eingeleitet | Wolfe Research | Outperform |
| 2023-12-12 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-11-17 | Herabstufung | UBS | Buy → Neutral |
| 2023-09-28 | Eingeleitet | Bernstein | Mkt Perform |
| 2023-07-31 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2023-05-24 | Bestätigt | Barclays | Equal Weight |
| 2023-05-24 | Bestätigt | BofA Securities | Buy |
| 2023-05-24 | Bestätigt | Citigroup | Neutral |
| 2023-05-24 | Bestätigt | Credit Suisse | Outperform |
| 2023-05-24 | Bestätigt | Evercore ISI | Outperform |
| 2023-05-24 | Herabstufung | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2023-05-24 | Bestätigt | Robert W. Baird | Outperform |
| 2023-05-24 | Bestätigt | SVB Securities | Outperform |
| 2023-05-24 | Bestätigt | Stifel | Hold |
| 2023-05-24 | Bestätigt | TD Cowen | Outperform |
| 2023-05-24 | Bestätigt | Wells Fargo | Overweight |
| 2023-05-11 | Eingeleitet | Barclays | Equal Weight |
| 2023-01-10 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-08-25 | Eingeleitet | Credit Suisse | Outperform |
| 2022-07-20 | Eingeleitet | UBS | Buy |
| 2022-07-08 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-04-25 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2022-02-23 | Bestätigt | BofA Securities | Buy |
| 2022-02-23 | Bestätigt | Citigroup | Buy |
| 2022-02-23 | Bestätigt | Cowen | Outperform |
| 2022-02-23 | Bestätigt | Evercore ISI | Outperform |
| 2022-02-23 | Bestätigt | Stifel | Hold |
| 2022-02-23 | Bestätigt | Wells Fargo | Overweight |
| 2021-11-23 | Bestätigt | BofA Securities | Buy |
| 2021-11-23 | Bestätigt | Cowen | Outperform |
| 2021-11-23 | Bestätigt | Stifel | Hold |
| 2021-03-18 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-02-17 | Hochstufung | BofA Securities | Neutral → Buy |
| 2020-12-02 | Eingeleitet | Goldman | Buy |
| 2020-11-25 | Hochstufung | UBS | Neutral → Buy |
| 2020-11-17 | Hochstufung | Cleveland Research | Neutral → Buy |
| 2020-11-10 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2020-09-30 | Eingeleitet | Atlantic Equities | Neutral |
| 2020-08-19 | Bestätigt | BofA Securities | Neutral |
| 2020-08-19 | Bestätigt | Citigroup | Neutral |
| 2020-08-19 | Bestätigt | Jefferies | Buy |
| 2020-08-19 | Bestätigt | Robert W. Baird | Outperform |
| 2020-08-19 | Bestätigt | SVB Leerink | Outperform |
| 2020-08-19 | Bestätigt | Stifel | Hold |
| 2020-08-19 | Bestätigt | Wells Fargo | Overweight |
| 2020-02-24 | Herabstufung | Needham | Buy → Hold |
| 2020-01-08 | Eingeleitet | Wells Fargo | Overweight |
| 2020-01-07 | Eingeleitet | Citigroup | Neutral |
| 2019-11-26 | Bestätigt | Needham | Buy |
| 2019-11-15 | Eingeleitet | Stifel | Hold |
| 2019-10-18 | Herabstufung | UBS | Buy → Neutral |
| 2019-07-16 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2019-07-15 | Herabstufung | Barclays | Overweight → Equal Weight |
Alle ansehen
Agilent Technologies Inc Aktie (A) Neueste Nachrichten
World Syringes for AgilentMarket Analysis, Forecast, Size, Trends and Insights - IndexBox
Agilent Technologies Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
A4996671 Bond Profile — Key Metrics - TradingView
A5886204 Bond Profile — Key Metrics - TradingView
A5886359 Bond Profile — Key Metrics - TradingView
Agilent Technologies (NYSE:A) Nears A Technical Breakout - Kalkine Media
Agilent Technologies (NYSE:A) Shows Strong Breakout Setup with Top-Tier Technical Ratings - ChartMill
Agilent Technologies (A) Receives FDA Approval for New Diagnosti - GuruFocus
Oligonucleotide CDMO Market to Reach USD 9.87 Billion by 2031 as RNA-Targeted Drug Pipelines Expand - GlobeNewswire Inc.
Agilent Technologies (A) Receives FDA Approval for PD-L1 IHC 28-8 pharmDx Kit - GuruFocus
Agilent Technologies Receives Fda Approval for Pd-L1 Ihc 28-8 Pharmdx in Esophageal Squamous Cell Carcinoma, Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma - marketscreener.com
Agilent receives FDA approval for cancer diagnostic test - Investing.com
Agilent receives FDA approval for cancer diagnostic test By Investing.com - Investing.com Canada
Agilent Receives FDA Approval for PD-L1 IHC 28-8 pharmDx in Esophageal Squamous Cell Carcinoma (ESCC), Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinoma - Business Wire
A6433334 Bond Profile — Key Metrics - TradingView
Agilent expands Altura HPLC column portfolio for biopharma By Investing.com - Investing.com Nigeria
Agilent Technologies stock reflects steady diagnostics demand - Ad Hoc News
Agilent (A): Buy, Sell, or Hold Post Q1 Earnings? - Yahoo Finance
Baird Adjusts Agilent Technologies Price Target to $160 From $158, Maintains Outperform Rating - marketscreener.com
Agilent Technologies, Inc. (A) Stock Analysis: Is There a Potential 18.56% Upside for Investors? - DirectorsTalk Interviews
Is Agilent Technologies (A) A Bargain Following Its New Lab Tools And AI Software? - Sahm
Why Is Agilent (NYSE:A) Launching New AI Chromatography Tools? - Kalkine Media
Tangible book value per share of Agilent Technologies, Inc. – LSX:929138 - TradingView
Agilent rises on Q2 beats; adjusts fiscal 2026 guidance - MSN
Agilent Unveils the 9500 ICP-MS: Redefining Trace Element Analysis - AOL.com
Agilent (NYSE:A) Deepens Its AI Biopharma Push - Kalkine Media
Agilent Technologies stock stays supported by life-science demand - ad-hoc-news.de
Does Agilent (A) Signal a Deeper Shift With New AI Biopharma Tools and Columns? - simplywall.st
Agilent Technologies Inc (A) Stock Up 3.5% and Still Undervalued -- GF Score: 93/100 - GuruFocus
Agilent Technologies Inc. stock outperforms competitors on strong trading day - MarketWatch
Agilent Strengthens Biopharma Growth Prospects With AI Expansion - Yahoo Finance
AGILENT TECHNOLOGIES, INC. CMNRo Khanna Congressional Trade on Jun. 30, 2026 - Quiver Quantitative
Agilent expands Altura portfolio with inert size exclusion and PLRP-S columns for biotherapeutic analysis - BioSpectrum Asia
Agilent Technologies explores long-term growth drivers as a life sciences leader - ad-hoc-news.de
Jefferies resumes Agilent stock coverage with Hold rating By Investing.com - Investing.com South Africa
Agilent Expands Altura Portfolio with Inert Size Exclusion and PLRP-S Columns for Biotherapeutic Analysis - Business Wire
Jefferies resumes Agilent stock coverage with Hold rating - Investing.com
symbol__ Stock Quote Price and Forecast - CNN
Agilent Technologies Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Agilent Technologies earnings and business outlook. Investors focus on diagnostics and life sciences - ad-hoc-news.de
Agilent Expands HPLC Column Portfolio to Enhance Biotherapeutic Analysis - Contract Pharma
Agilent Technologies Inc. Expands Altura Portfolio with Inert Size Exclusion and Plrp-S Columns for Biotherapeutic Analysis - marketscreener.com
Is Agilent Technologies, Inc. (A) Stock Positioned for Growth as Life Sciences Sector Trends Stabilize? - Yahoo Finance
Agilent Slumps on Expansion Plans - TradingView
Agilent expands Altura HPLC column portfolio for biopharma - Investing.com
Agilent adds inert columns for tougher biopharma tests - Stock Titan
Agilent adds SEC and PLRP-S columns to Altura portfolio - StreetInsider
Agilent Technologies focuses on analytical solutions as investors watch long-term growth - ad-hoc-news.de
Agilent 1260 Infinity II LC from Agilent Technologiesworkhorse HPLC for busy US labs - ad-hoc-news.de
Agilent 6560 Ion Mobility LC/Q-TOF from Agilentniche lab workhorse gains quiet momentum - AD HOC NEWS
Agilent (A) Stock Looks Below Fair Value On Cash Flow - Yahoo Finance
Finanzdaten der Agilent Technologies Inc-Aktie (A)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.72%
0.87%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):